Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology
Agreement adds cutting-edge innovation to Galderma’s aesthetic injectable portfolio, the aesthetic industry’s broadest injectable range
Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021
RESTYLANE® EYELIGHT™ to launch as new targeted treatment solution for under-eye shadows
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
Data supporting the positive decision demonstrated that patients treated with Alluzience® for wrinkles had a rapid onset of effect starti
How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth
Cécile Dussart discusses ESG being an integral part of Galderma's business
RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement
The unsurpassed NASHA™ technology, which is still used today as the benchmark for fillers, was pioneered by Galderma
Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe
Updated administration protocol means Sculptra® offers the fastest reconstitution of any injectable PLLA available in Europe.
Represents second approved indication for Restylane® DEFYNE™ in U.S.
Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®.